anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The patients included in the experimental group will be operated on, performing the resection of the intestinal segment affected by the dehiscence, the sectioned intestinal ends will be left without anastomosis, and open abdomen therapy will be established. After surgery, the patient will be cared for in the intensive care unit where intensive resuscitation will be carried out in order to improve the general conditions of the patient. After 48 ± 24 hours, a second surgical procedure will be performed where local conditions will be evaluated and the possibility of performing a delayed anastomosis will be evaluated.
In this protocol, a repeated measure design is used to examine microbial and molecular results in subjects with a diagnosis of pulmonary nontuberculous mycobacterial infection. Patients often experience difficulties in the spontaneous expectoration of sputum free from contamination with oral flora which contributes to the poor quality of some respiratory specimens sent to the laboratory. At present, it is not known how induced sputum, expectorated sputum, and pharyngeal swabs compare for acid fast bacilli (AFB) smear and culture results. Appropriate specimens are needed in the clinical setting for optimum diagnosis. In this study, procedures for the non-invasive collection of respiratory secretions will be used to decrease risk of specimen contamination.

Subjects who cannot produce respiratory secretions will be compared to patients who are successful. It is not known which factors prevent production of respiratory secretions for testing. Airway inflammation may contribute to difficulty in producing sputum along with dyspnea, phase of illness (newly diagnosed or chronic infection), treatment status, and respiratory condition severity.

Subjects will be characterized by phase of illness determined by health history and inflammation using common laboratory tests of inflammation. Respiratory specimens and blood will be collected for microbial testing and a portion will be stored then tested for analysis of pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-alpha, \& IFN-gamma). Clinical, demographic, laboratory, and patient subjective variables will be tested using regression statistical methods to determine predictors for specimen production success. Clinical variables to be tested include forced expiratory volume at one minute (FEV1) from a pulmonary function test (PFT), phase of illness and treatment, and age. The laboratory tests indicating inflammation include erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Beta-2-Microglobulin (Beta-2M). Patient assessments for dyspnea will be evaluated using the Borg questionnaire.
PURPOSE: A cosmetic formulation with improved stability and solubility is provided to contribute stabilization of an active ingredient. CONSTITUTION: A cosmetic composition of a novel formulation with enhanced solubility is prepared by granulating xanthan gum into powder containing skin active ingredients. The granule is prepared using a fluidized bed top spray system. The cosmetic composition contains 0.2-0.5 wt% of starch. The granule size of enhancing solubility is No. 20-60.
Depression is an independent risk factor for coronary artery disease (CAD); unfortunately, past trials have not detected a cardiovascular benefit. A promising and unexplored explanation for these results is that the interventions were delivered too late in the natural history of CAD. Because no study has evaluated this possibility, there is a critical need to determine whether evidence-based depression treatment, delivered before the onset of clinical CAD, reduces cardiovascular risk. Accordingly, the objective of the proposed clinical and translational research is to perform a preliminary evaluation of the efficacy of a highly disseminable depression intervention in decreasing CAD risk. To achieve this goal, a clinical trial of depressed primary care patients free of cardiovascular disease is being conducted. Patients will be randomized to usual care or a computer-based, cognitive behavioral intervention called Beating the Blues®, the most widely used and empirically supported computerized treatment program for depression. The primary outcome is brachial artery flow-mediated dilation, a noninvasive measure of endothelial function. The specific aim of the proposed trial is to evaluate whether Beating the Blues®, delivered prior to the onset of clinical CAD, improves endothelial dysfunction. Demonstrating that earlier treatment of depression with Beating the Blues lowers CAD risk, the long-term expected outcome, would place computed-based depression treatment in the armamentarium of CAD prevention strategies of the primary care provider. This change to clinical practice should result in improved cardiovascular risk management, which in turn would translate into reduced CAD morbidity and mortality.
A process for producing a fluid soluble cannabis base product that is used primarily to create an ingestible liquid with the benefits and effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the cannabis. The process separates different cannabinoids in a cannabis plant and reconstitutes the cannabinoids into a fluid soluble solution having both the THC and CBD. By utilizing hydroxyl functional groups, cannabis plant material is converted into a fluid soluble solution. Then using reverse osmosis, remaining unmodified hydroxyl functional groups are removed through a semipermeable membrane acting as a filter. The remaining product is processed through four phases in which the product undergoes further thermos and kinetic modifications with hydrogen 2 oxygen 1 (H20). The end product is a fluid soluble or fluid compatible solution.
Defined as patients who did not fill at least two prescriptions for pioglitazone within a 6-month period. Patients in the pioglitazone unexposed group may have been exposed to other diabetic medications. This group also included diabetic patients without any diabetic medications.
Thioridazine has been shown to prolong the QTc interval in a dose related manner, and drugs with this potential, including thioridazine, have been associated with Torsades de pointes type arrhythmias and sudden death. Due to its potential for significant, possibly life threatening, proarrhythmic effects, thioridazine should be reserved for use in the treatment of schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs (see WARNINGS, CONTRAINDICATIONS, and INDICATIONS). 

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of seventeen placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear. Thioridazine hydrochloride is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
Transanal ice pack is applied to hemorrhoidectomy wound for 1 minute. After the surgery, standard postoperative analgesia and medications will be prescribed.
The obese heart undergoes metabolic remodeling and exhibits impaired calcium (Ca2+) homeostasis, which are two critical assaults leading to cardiac dysfunction. The molecular mechanisms underlying these alterations in obese heart are not well understood. Here, we show that the Rab-GTPase activating protein AS160 is a lipid-responsive regulator of Ca2+ homeostasis through governing lysophosphatidylinositol metabolism and signaling. Palmitic acid/high fat diet inhibits AS160 activity through phosphorylation by NEK6, which consequently activates its downstream target Rab8a. Inactivation of AS160 in cardiomyocytes elevates cytosolic Ca2+ that subsequently impairs cardiac contractility. Mechanistically, Rab8a downstream of AS160 interacts with DDHD1 to increase lysophosphatidylinositol metabolism and signaling that leads to Ca2+ release from sarcoplasmic reticulum. Inactivation of NEK6 prevents inhibition of AS160 by palmitic acid/high fat diet, and alleviates cardiac dysfunction in high fat diet-fed mice. Together, our findings reveal a regulatory mechanism governing metabolic remodeling and Ca2+ homeostasis in obese heart, and have therapeutic implications to combat obesity cardiomyopathy.
Phase IIB trial of 6 months of BZA 20 mg +CE 0.45 mg (subsequently designated as BZA+CE) vs a waitlist control. Trial is informed by prior results of a single arm trial that used Duavee® (combination of BZA+CE that is FDA-approved for relief of hot flashes). Since Duavee® is currently not available commercially, the two separate components are used instead. Breast imaging, benign breast tissue by RPFNA, and blood for biomarkers will be obtained at baseline and at 6 months using similar assessment techniques. The primary endpoint is the difference between the BZA+CE and control groups for absolute change from baseline to 6 months in the risk biomarker fibroglandular volume (FGV). Volpara® fully automated assessments overcome the interpretive variance inherent in subjective assessments. Additional endpoints include changes in benign breast epithelial immunolabeling for Ki-67, estrogen receptor alpha (ERα), progesterone receptor (PR), and anterior gradient-2 protein (AGR2); and systemic levels of bioavailable hormones, IGF-1, IGFBP3, and measures of insulin sensitivity. The modifying effects of baseline BMI, visceral adipose, and plasma BZA concentrations on markers will be studied.
Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality. They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months.
INTRODUCTION: Renal colic is the most common non-obstetric cause of abdominal pain during pregnancy and is associated with a higher risk of complications in these women. When invasive treatment is required, options are temporary drainage with ureteral stent (JJ) or percutaneous nephrostomy (PCN), or immediate definitive treatment with ureteroscopy (URS). Our goal was to review the safety and efficacy of these procedures in treating urolithiasis during pregnancy.
METHODS: Adhering to the PRISMA checklist guidelines, we searched PubMed, Embase, and Scopus databases for articles on the efficacy and complications of the three procedures in pregnant women. The quality of evidence and risk of bias were evaluated using the Critical Appraisal Skills Programme and the Institute of Health Economics tools.
RESULTS: We included 45 articles, totaling 3424 interventions in pregnant women - 2188 URS, 719 JJ, and 517 PCN. URS was the most assessed procedure, with stone-free rates comparable to the non-pregnant patients. The most frequent complications were lower urinary symptoms and infections independently of the intervention. Obstetric complications for all interventions included 167 cases of preterm labor, resulting in 24 premature births. No statistically significant differences in post-operative complications were reported between the procedures in the few comparative studies.
CONCLUSIONS: Despite the absence of high-quality studies, current evidence suggests that URS, JJ, and PCN are all safe and effective during pregnancy. As most patients submitted to temporary drainage require a second procedure post-delivery, primary URS appears more efficient. Therefore, it is the preferred option unless there are indications for temporary drainage.
PROBLEM TO BE SOLVED: To obtain the subject new inhibiting agent useful in food and medicinal fields by incorporating a conjugated linolenic acid. SOLUTION: This breast cancer-inhibiting agent contains a conjugated linolenic acid (e.g. 9,11,13-octadecatrienic acid, 10,12,14octadecatrienic acid, their mixture, etc.). As the form of the conjugated linolenic acid, the fatty acid, a mono-, di- or triglyceride, a sodium salt, a potassium salt, a phospholipid, a lyzophospholipid and their mixture can be cited. The breast cancer-inhibiting agent can be used not only as a medicine but also as a breast cancer-inhibiting or preventing food (e.g. a conjugated linolenic acid-containing oil and fat product), and in both cases of usages, the conjugated linolenic acid to be ingested is generally 0.01-3%, preferably 0.05-1% of the weight of the food.
Subjects aged between and including 12 and 15 months at the time of booster vaccination who received the Infanrix hexa vaccine in the primary study and a booster dose of Infanrix hexa in this study, co-administered with a booster dose of Prevenar 13. The Infanrix hexa and Prevenar 13 vaccines were administered intramuscularly into the right and left sides of the thigh, respectively.
MSM randomized to the AMC arm will receive twice weekly digital media messages for 12 weeks about general health and a link to a study-specific webpage listing testing resources and MSM-specific services. Participants will also be able to interact with online outreach workers.
PCT No. PCT/DE87/00174 Sec. 371 Date Jan. 14, 1988 Sec. 102(e) Date Jan. 14, 1988 PCT Filed Apr. 16, 1987 PCT Pub. No. WO87/06144 PCT Pub. Date Oct. 22, 1987.A transdermal therapeutic system is disclosed which comprises an optional flexible backing layer, one or more drug reservoir(s), one or more adhesive layer(s) and optionally a detachable protective layer for the skin contact surface of the flat therapeutical system. The skin contact area of the therapeutical system is a skin contact layer which has one or more non-adhesive drug-releasing section(s) and one or more skin-adhesion section(s), which optionally contain a further drug. A process is disclosed for the production of the system, as well as the use thereof for local or systemic, transdermal administration of drugs in human or veterinary medicine or in cosmetics.
[US5132115A]
NEW MATERIAL:A biotin ester of the formula (R is 5-20C straight chain saturated or unsaturated alcohol, 5-24C branched alcohol, 5-30C alicyclic alcohol, pyridinemethanol or the alcohol residue of dl-alpha-tocophenol). EXAMPLE:Biotin n-octyl ester. USE:Useful an active integrated for skin external agents preventing and improving skin irritations for hair tonics used for preventing and treating alopecia. Biotin accelerates the synthesis of fatty acids and cholesterol in living bodies and exhibits various useful physiological functions such as the growth acceleration of hair, the dissolution of the compound of formula I in water, oil, etc., is bad. The compound of the formula improves the solubility thereof without damaging the pharmacological action thereof. PREPARATION:For example, biotin is esterified in the presence of a catalyst in a non-reactive solvent such as benzene while azeotropically removing the by-produced water, thereby providing the compound of formula I.
A method and system of generating a recovery score for a user. The method comprises obtaining a measure, HR first , of the heartrate of the user when in a first position (S601). The method comprises obtaining a measure, HRV first , of the heartrate variability of the user when in the first position (S602). The method comprises obtaining a measure, HR second , of the heartrate of the user when in a second position (S603). The method comprises obtaining a measure, HRV second , of the heartrate variability of the user when in the second position (S604). The method further comprises generating the recovery score using HR first , HRV first ,HR second , and HRV second  (S605).
The invention discloses a Chinese herbal medicine used for treating cough and celostomia. The Chinese herbal medicine is prepared by adding 3-10 parts of prepared apricot kernel, 6-15 parts of Zhejiang fritillaria bulb, 5-10 parts of rhizoma anemarrhenae, 3-10 parts of mulberry bark, 3-7 parts of akebia stem, 3-7 parts of Chinese magnoliavine fruit, 4-9 parts of coltsfoot flower, 5-10 parts of radix scrophulariae, 5-10 parts of radix scutellariae, 5-8 parts of fresh ginger, 5-8 parts of radix ophiopogonis and 5-10 parts of gingko into a marmite, adding 1200 parts of water, cooking with slow fire for 20-30 min after the mixture is boiled, filtering to obtain a liquid supernatant, cooking for three times, uniformly mixing the three liquid supernatants in the three cooking steps, subpackaging into bottles, sterilizing at high temperature, and keeping for being taken. The Zhejiang fritillaria bulb is adopted as the monarch. The prepared apricot kernel is adopted as the minister. The mulberry bark, the akebia stem, the Chinese magnoliavine fruit and the coltsfoot flower are adopted as assistants. The radix scrophulariae, the radix scutellariae, the fresh ginger, the radix ophiopogonis and the gingko are adopted as guides. The medicine is low in production cost, safe to take, and free of side and toxic effects. The taking effects are practiced in clinic and the cost of the medicine is low. The Chinese herbal medicine is an ideal medicine used for treating cough and celostomia.
Patients receive oral cyclophosphamide once daily and oral celecoxib twice daily. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
BACKGROUND: Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a significant risk of morbidity and mortality in surgical patients, especially those undergoing head and neck cancer surgery with microvascular free flap reconstruction. These patients are at a heightened risk of VTE due to numerous patient and surgical risk factors. VTE chemoprophylaxis guidelines in these patients are limited due to a distinct paucity of research. This study aims to contribute to this scarcity of information, providing guidance for surgeons.
METHODS: This retrospective cohort study evaluated the efficacy and safety of subcutaneous unfractionated heparin administered every 8 h versus every 12 h for postoperative VTE prophylaxis in patients undergoing head and neck resections with immediate free flap reconstruction. Data was collected from hospital medical records between January 2010 to December 2021. Patient demographics, operative details, and outcomes, including incidence of VTE and bleeding complications, were analyzed.
RESULTS: Among 622 patients, those receiving heparin every 8 h (n = 393) demonstrated a significantly lower rate of VTE (0.8%) compared to 12-hourly group (n = 229; 3.9%) (p = 0.006). Additionally, there were no significant differences in the rates of postoperative hematoma between the two groups (9.4% versus 7.9% respectively, p = 0.510).
CONCLUSION: Our study suggests that an increased daily dose of unfractionated heparin every 8 h for VTE chemoprophylaxis is superior to a 12-hourly regimen with comparable bleeding profiles. Further multicentre, prospective studies are needed to validate these results and compare the efficacy and safety of unfractionated heparin with other agents such as low-molecular-weight heparin in this patient group.
A method for non-invasive blood glucose monitoring with a wearable device may include illuminating, with an electromagnetic source module of a wearable device, an area of skin of a user. The method may include measuring a scattered electromagnetic energy reflected from the area of skin with an electromagnetic receiver module of the wearable device. The method may include calculating, with a processor coupled to the electromagnetic receiver module, a blood glucose level in response to the measurement of the scattered electromagnetic energy reflected from the area of skin. The method may include communicating the blood glucose level to an information handling system. The electromagnetic source module may include a photodiode or a microwave module. The information handling system may include an application configured for a smart phone, tablet, or computer. The information handling system may include a memory configured for storing a historical record including multiple blood glucose levels.
Subjects ages 18-85 years old with biopsy proven melanoma. Peripheral blood will be collected from adults ages 18-85 years old. These samples will then be used for PCR analysis and to generate melanoma-specific T cell clones. If the participant requires a palliative resection of a melanoma tumor(s) then tissue from the tumor will be used to characterize the melanoma's interaction with the immune system and to generate melanoma-specific cell lines. T cell clones isolated from participant's peripheral blood will then be assayed for in-vitro responsiveness to these cell lines. All experiments will be conducted in-vitro.
Torsion is the twisting of an object along the axis, and various structures (organs and tumors) in the body can twist. Torsion causes initial lymphatic and venous outflow obstruction, leading to congestive edema, enlargement, venous hemorrhagic infarction, and surrounding edema. It can also cause subsequent arterial obstruction depending on the degree of torsion, leading to ischemia, infarction, necrosis, gangrene, and surrounding inflammation. Therefore, in several cases of torsion, immediate surgical intervention is required to improve blood flow and prevent serious complications. Clinical manifestations of torsion are often nonspecific and can affect individuals of varying ages and sex. Imaging plays an important role in the early diagnosis and management of torsion. Multiple imaging modalities, including US, radiography, CT, and MRI, are used to evaluate torsion, and each modality has its specific characteristics. The imaging findings reflect the pathophysiologic mechanism: a twisted pedicle (whirlpool sign), enlargement of the torsed structures, reduced blood flow, internal heterogeneity, and surrounding reactive changes. The whirlpool sign is a definitive characteristic of torsion. In some cases, despite poor internal enhancement, capsular enhancement is observed on contrast-enhanced CT and MR images and is considered to be associated with preserved capsular arterial flow or capsular neovascularization due to inflammation. Radiologists should be familiar with the pathophysiologic mechanisms, clinical characteristics, and imaging characteristics of torsion in various structures in the body. Since other articles about common organ torsions already exist, the authors of this article focus on the uncommon entities that manifest with torsion. ©RSNA, 2024.
This is a single arm (one group of patients), open-label (all people know the identity of the intervention) multicenter 6-month study. Throughout the study flexible dosing of paliperidone ER in a range of 3 to 12 mg/day may be used. Flexible dosing will allow investigators to adjust the dosage of each patient based on the individual needs. Patients will receive 3, 6, 9 or 12 mg of paliperidone ER once daily for 6 months. The tablets will be taken orally. Adjustment of the dosage will be done at the investigator's discretion, based on the individual patient's clinical response and tolerability to the study drug.